Progesterone Resistance: The Missing Link
For decades, progesterone has been approached as a simple numbers game: measured in serum, adjusted with supplementation, and interpreted through the lens of deficiency. If levels are low, we replace. If symptoms persist, we increase the dose. But this model assumes something that is increasingly being challenged: that the presence of progesterone guarantees its effect.
Hormones As Communication Signals
In reality, hormones do not act in isolation, and they do not act passively. They communicate. And like any communication system, what matters is not just the signal being sent, but whether it is received.
Progesterone exerts its effects through progesterone receptors: primarily PR-A and PR-B, located within target tissues such as the endometrium, brain, and immune cells. These receptors act as transcription factors, translating hormonal signals into physiologic outcomes: stabilizing the uterine lining, modulating inflammation, and supporting the calming, GABA-mediated effects many patients associate with progesterone. But the effectiveness of this system depends on more than hormone availability. It depends on receptor function.
This introduces a critical and often overlooked concept: progesterone resistance.
Progesterone Resistance: The Missing Link
Much like insulin resistance, progesterone resistance describes a state in which adequate, or even elevated, levels of hormone fail to produce an appropriate biological response. The issue is not supply, but sensitivity. Patients may present with symptoms suggestive of low progesterone, premenstrual mood changes, disrupted sleep, infertility, or persistent estrogen dominance, despite laboratory values that appear sufficient. In these cases, the signal is present, but the message is not being received.
What Disrupts Progesterone Signaling
The reasons for this are multifactorial. At the receptor level, both the number and function of progesterone receptors can be altered. Chronic inflammation, oxidative stress, and certain disease states such as endometriosis and PCOS have been shown to reduce receptor expression or shift the balance between receptor subtypes, particularly decreasing the activity of PR-B, which is critical for many of progesterone’s protective effects. Even when receptors are present, post-receptor signaling may be impaired, preventing the downstream actions that progesterone is meant to initiate.
Androgen Signaling and Hormonal Crosstalk
Layered onto this is the broader hormonal environment - particularly the role of androgen signaling.
The androgen receptor contains a polymorphic region characterized by CAG repeats, which directly influence receptor sensitivity. Individuals with shorter CAG repeat lengths exhibit heightened androgen receptor activity, meaning that a given level of testosterone can exert a more pronounced biological effect. This becomes particularly relevant in conditions like PCOS, where androgen levels may already be elevated.
While progesterone and androgens are often discussed separately, their signaling pathways are not independent. Steroid hormone receptors share co-regulators and intracellular signaling machinery, creating an environment of constant crosstalk and competition. Enhanced androgen signaling, particularly in individuals with genetically more sensitive androgen receptors, may shift this balance, altering the availability of shared coactivators and subtly dampening progesterone’s ability to exert its effects.
A Broader View of Hormonal Imbalance
In this context, progesterone resistance is not simply a standalone issue, but part of a broader network of hormonal signaling dynamics. A patient with normal progesterone levels, increased androgen receptor sensitivity, and underlying inflammation may experience a compounded effect: diminished progesterone signaling despite adequate hormone availability.
This reframes how we interpret both labs and symptoms. It challenges the assumption that more progesterone is always the solution and instead encourages a more nuanced approach—one that considers receptor health, cellular environment, and hormonal interplay.
A More Integrative Therapeutic Approach
It also opens the door to a more integrative therapeutic strategy. Addressing inflammation, improving metabolic health, and supporting cellular resilience, through pathways such as NRF2 activation, may enhance hormone responsiveness at the receptor level. In doing so, we are not merely increasing hormone levels, but restoring the body’s ability to respond to them.
Ultimately, this perspective shifts progesterone from a static value to a dynamic signal, one that depends as much on the integrity of the system receiving it as on the hormone itself.